Dynamic assessment of quality of life after autologous bone marrow transplantation

Autor: NJ Chao, DK Tierney, JR Bloom, GD Long, TA Barr, BA Stallbaum, RM Wong, RS Negrin, SJ Horning, KG Blume

Publikováno v: Blood. 80(3)

To determine the quality of life in adult patients after autologous bone marrow transplantation (BMT), we administered a questionnaire to a cohort of patients seen at a single referral-based center. The sample included adults 18 years and older durin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::470add4c279572e40dec4501021a2c33
https://pubmed.ncbi.nlm.nih.gov/1638031

The treatment of malignant histiocytosis

Autor: A Jr Tseng, CN Coleman, RS Cox, TV Colby, RR Turner, SJ Horning, SA Rosenberg

Publikováno v: Blood. 64(1)

Twenty-four consecutive cases of malignant histiocytosis (MH) treated at Stanford Medical Center between 1973 and 1983 have been reviewed. Most patients presented with systemic symptoms (91%) and advanced disease (stage IV, 80%). Multiple organ invol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e85f95e3a5d8f5dc72ca8f4f60a8325f
https://pubmed.ncbi.nlm.nih.gov/6610448

Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.

Autor: Erbe AK; Department of Human Oncology, University of Wisconsin, Madison, WI, USA., Wang W; Department of Human Oncology, University of Wisconsin, Madison, WI, USA., Carmichael L; Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA., Hoefges A; Department of Human Oncology, University of Wisconsin, Madison, WI, USA., Grzywacz B; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA., Reville PK; Department of Human Oncology, University of Wisconsin, Madison, WI, USA., Ranheim EA; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA., Hank JA; Department of Human Oncology, University of Wisconsin, Madison, WI, USA., Kim K; Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA., Seo S; Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA., Mendonca EA; Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA.; Department of Pediatrics, University of Wisconsin, Madison, WI, USA., Song Y; Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA., Kenkre VP; Department of Medicine, University of Wisconsin, Madison, WI, USA., Hong F; Department of Biostatistics, Harvard University, Dana Farber Cancer Institute, Boston, MA, USA., Gascoyne RD; Department of Pathology and Laboratory Medicine, Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, British Columbia, Canada., Paietta E; Montefiore Medical Center-North Division, Albert Einstein College of Medicine, Bronx, NY, USA., Horning SJ; Department of Medicine, Stanford University, Stanford, CA, USA., Miller JS; Department of Medicine, University of Minnesota, Minneapolis, MN, USA., Kahl B; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA., Sondel PM; Department of Human Oncology, University of Wisconsin, Madison, WI, USA. pmsondel@humonc.wisc.edu.; Department of Pediatrics, University of Wisconsin, Madison, WI, USA. pmsondel@humonc.wisc.edu.; University of Wisconsin-Madison, 1111 Highland Avenue, 4159 WIMR Bldg, Madison, WI, 53705, USA. pmsondel@humonc.wisc.edu.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2019 Mar 12; Vol. 7 (1), pp. 70. Date of Electronic Publication: 2019 Mar 12.

Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by ⁹⁰ Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499.

Autor: Smith MR; Fox Chase Cancer Center, Philadelphia, PA, USA., Hong F; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA, USA., Li H; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA, USA., Gordon LI; Northwestern University, Chicago, IL, USA., Gascoyne RD; British Columbia Cancer Agency, Vancouver, BC, USA., Paietta EM; Montefiore Medical Center, Bronx, NY, USA., Advani RH; Stanford University, Stanford, CA, USA., Forero-Torres A; University of Alabama, Birmingham, AL, USA., Horning SJ; Stanford University, Stanford, CA, USA., Kahl BS; University of Wisconsin, Madison, WI, USA.

Publikováno v: Leukemia [Leukemia] 2017 Feb; Vol. 31 (2), pp. 517-519. Date of Electronic Publication: 2016 Oct 26.

Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402.

Autor: Williams ME; University of Virginia Cancer Center, Charlottesville, VA, USA., Hong F; Dana Farber Cancer Institute, Boston, MA, USA., Gascoyne RD; British Columbia Cancer Agency, Center for Lymphoid Cancer, Vancouver, BC, Canada., Wagner LI; Northwestern University, Chicago, IL, USA., Krauss JC; University of Michigan, Ann Arbor, MI, USA., Habermann TM; Mayo Clinic, Rochester, MN, USA., Swinnen LJ; Johns Hopkins University, Baltimore, MD, USA., Schuster SJ; University of Pennsylvania, Philadelphia, PA, USA., Peterson CG; Aspirus Regional Cancer Center, Wausau, WI, USA., Sborov MD; Fairview-Southdale Hospital, St. Louis Park, MN, USA., Martin SE; Christiana Care CCOP and the Helen F. Graham Cancer Network, Newark, DE, USA., Weiss M; Marshfield Clinic, Marshfield, WI, USA., Ehmann WC; Penn State Cancer Institute, Hershey, PA, USA., Horning SJ; Genentech, Inc., South San Francisco, CA, USA., Kahl BS; Washington University School of Medicine, St. Louis, MO, USA.

Publikováno v: British journal of haematology [Br J Haematol] 2016 Jun; Vol. 173 (6), pp. 867-75. Date of Electronic Publication: 2016 Mar 11.